Armed with Nestlé cash, Aimmune grabs experimental food allergy drug form Xencor

Aimmune has had a good few weeks: It’s just won approval for the first peanut allergy drug at the FDA, then got a $200 million boost from Nestlé, and today it’s using that cash to license a new drug from Xencor.